At the news
? NEUTRALIMPACT 4/10 8-K filed May 12, 2026 at 17:00 ET
Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage profile, with a net loss of $19.1M ($0.22/share) vs. consensus of $-0.20. The key event is the reiteration of mid-2026 timelines to file the NDV-01 IND and initiate the Phase 3 RESCUE registrational program, supported by a $234M cash balance (post $160M PIPE) funding operations through 2029. The filing is neutral, no financial beat or miss, no guidance change, and the clinical milestones were already telegraphed in the prior quarter's update.
- Q1 2026 net loss of $19.1M ($0.22/share) vs. consensus $-0.20, a 12.8% miss on EPS
- Cash, cash equivalents, and short-term investments of $234.0M as of March 31, 2026, including ~$150M net from March 2026 PIPE
- On track to file NDV-01 IND and initiate Phase 3 RESCUE program in mid-2026
- Filed provisional patent application for NDV-01 in April 2026, with potential protection until 2047
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access